Search Results

AIM ImmunoTech Inc. today announced that it has received authorization from the Erasmus Medical Center (“Erasmus MC”) Ethics Committee to open a European site for the ongoing Phase 2 study (“AMP-270”) of Ampligen as a therapy for locally advanced pancreatic cancer.

MC2 Therapeutics confirms it has received positive feedback from a pre-Investigational New Drug meeting with the US Food and Drug Administration with respect to its first-in-class, oral drug candidate MC2-32 for the treatment of Hidradenitis Suppurativa.

Saranas, Inc. announced today the compelling results of SAFE-MCS, a multi-center clinical study evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with the Early Bird ® Bleed Monitoring System (EBBMS).

TransCode Therapeutics, Inc. today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity.

MC2 Therapeutics today announced it has completed enrollment in its European Phase 2 trial assessing the safety and efficacy of MC2-25 CKD, an innovative new drug candidate for the treatment of urea associated skin diseases, incl.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF) announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.

Rhythm Pharmaceuticals, Inc. today announced that the first patients have been dosed in the Company’s Phase 1 clinical trial of RM-718, an investigational, weekly melanocortin-4 receptor (MC4R)-specific agonist designed to be MC1R-sparing and to potentially avoid hyperpigmentation.